General Dermatology 

Eczema

Chronic Hand Eczema

Alopecia

Aesthetics

Vitiligo

COVID-19

Actinic Keratosis 

Precision Medicine and Biologics

Rare Disease

Wound Care

Rosacea 

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Melasma

NP and PA

Skin Cancer (Nonmelanoma)

Skin Cancer

Hidradenitis Suppurativa

Drug Watch

Pigmentary Disorders 

Acne 

Pediatric Dermatology

Practice Management 

Prurigo Nodularis

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Articles

A message of gratitude to the dermatology community for 45 years of collaboration, insights, and advancing care worldwide.

A Thankful Tribute to Our Dermatology Community

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Learn more about the in-depth topics covered in the November 2024 print issue of Dermatology Times.

Dermatology Times November 2024 Print Recap

Patients treated with radiofrequency microneedling and Cysteamine cream saw significant improvement in melasma severity and skin texture.

Combination Therapy of RFM and Cysteamine Effective in Treating Melasma

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

Advances in HS treatment with Chris Sayed, MD

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Chapter 1

OX40-Ligand (OX40L) Pathway Resource Center

Highlighting unmet needs in atopic dermatitis (AD) and understanding disease pathogenesis

Chalk Talk - Understanding the Role of the OX40L Pathway in AD

This material is for scientific and medical education purposes only, and is intended only for US healthcare professionals.

MAT-US-2410187 v1.0 - P Expiration Date: 11/08/2025